In vivo activity of NNRTI BBP153 against wildtype HIV-1

Pritsana Khamchaew, Edwin ten Winkel, bbPharma
BBP153, is shown to have potent in vitro activity, high genetic barrier to resistance development and favorable pharmacokinetics.

In Vitro Activity
BBP153, a new NNRTI, exhibits potent in vitro anti-HIV activity with an EC₅₀ against wild-type HIV-1 of 0.5 nM, and little or no loss of activity against HIV-1 variants having key NNRTI resistance mutations.

This might be a result of the adaptability of the interaction between BBP153 and the NNRTI binding site of HIV-1 reverse transcriptase which allows the compound to bind in different modes and adjust in case of RT mutations.